An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Genentech
- 06 Jun 2017 Interim safety results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Aug 2016 Status changed from recruiting to completed.
- 08 Aug 2016 Status changed from completed to recruiting.